A 25-member panel says hormone therapy after breast cancer should be a shared decision

Breast cancer treatment frequently induces menopause, or worsens it. Chemotherapy can end ovarian function; endocrine therapy for oestrogen-receptor-positive disease deliberately suppresses oestrogen for years. The resulting symptoms — vasomotor, genitourinary, sleep, sexual — are often more severe than those of natural menopause, and the standard treatment for them is the one class of drug most breast cancer patients are told to avoid.

A consensus statement published in the January issue of Menopause addresses that impasse [s1]. It does not resolve it, and it does not claim to.

What the statement is

A multidisciplinary panel of 25 members used a modified Delphi methodology to develop consensus on menopausal hormone therapy after breast cancer [s1]. Modified Delphi is a structured process in which experts rate statements across iterative anonymous rounds until agreement thresholds are met. It produces agreement, which is not the same as evidence.

The evidence review that accompanied it identified mainly moderate-quality data on vaginal and systemic oestrogen use following a breast cancer diagnosis, alongside high-quality evidence supporting anti-oestrogen therapy for oestrogen-receptor-positive disease [s1].

That asymmetry is the crux. The case for suppressing oestrogen in ER-positive breast cancer rests on high-quality evidence. The case for or against giving oestrogen back, to the same patients, for symptom control, rests on moderate-quality evidence.

What the panel agreed

The panel agreed that some women may choose to take menopausal hormone therapy — an off-label use — and accept an increased risk of relapse in exchange for relief from menopausal symptoms [s1].

Every respondent supported shared decision-making and individualised care [s1]. The recommended basis for those decisions has three components: an individual's menopausal symptoms and their impact on quality of life; the potential increase in that individual's risk of relapse from using menopausal hormone therapy; and patient preferences [s1].

The panel also strongly recommends that all patients considering hormone therapy after cancer be enrolled in clinical studies, naming the MENO-ABC trial [s1].

Reading the phrasing carefully

The wording of the central agreement is precise and deserves to be read as written. It does not say hormone therapy is safe after breast cancer. It does not say the relapse risk is small, or uncertain, or overstated. It says some women may choose it and accept an increased risk of relapse [s1].

That framing concedes the risk and relocates the decision. It is a statement about who decides rather than about what the evidence shows.

There is a reasonable case for that move. The alternative — a blanket prohibition — has a cost that falls entirely on patients, and it is a cost clinicians do not bear or measure. Severe untreated vasomotor symptoms, genitourinary syndrome, and sleep disruption over years are not trivial, and they are the predictable consequence of the treatment that saved the patient's life.

There is also a reasonable objection. Shared decision-making requires a quantified risk to share, and moderate-quality evidence [s1] does not readily produce an individualised relapse-risk figure that a patient can weigh against her symptoms. A framework that says "decide together" without a number to decide on places substantial weight on the quality of the individual consultation.

The panel's strong recommendation to enrol these patients in studies [s1] can be read as an acknowledgement of exactly that gap.

What is not settled here

The statement covers both vaginal and systemic oestrogen [s1], and these are not the same intervention. Low-dose vaginal oestrogen for genitourinary symptoms produces minimal systemic absorption and has a different risk profile from systemic hormone therapy; the evidence bases differ, and readers should not treat conclusions about one as applying to the other.

Nor does a consensus statement change practice on its own. It has no regulatory force, the use it describes is off-label [s1], and oncology and menopause societies do not necessarily agree with one another on this question. A Delphi consensus reflects the views of the 25 people convened.

Why it is published now

The wider context is a period of reassessment of menopausal hormone therapy generally, including of how risks established in the Women's Health Initiative era have been communicated since. Breast cancer survivors have been at the far end of the resulting caution — the group most comprehensively excluded from treatment.

This statement is an attempt to reopen that question in a structured way rather than to answer it. Its most defensible contribution is the explicit acknowledgement that declining to treat is itself a choice with consequences, and that the person bearing those consequences has standing in the decision.

What to watch

Results from the MENO-ABC trial [s1]; whether oncology bodies respond with concurring or dissenting guidance; and whether any of the moderate-quality evidence on vaginal oestrogen after breast cancer is upgraded by new trials.

This article describes a published consensus statement and is informational only. It is not medical advice and does not recommend any treatment. Hormone therapy after breast cancer is an off-label use with an acknowledged relapse risk, and decisions about it belong with a patient and her oncology and menopause clinicians.

Sources

• [s1] Glynne S, Simon J, Branson A, Payne S, Newson L, Manyonda I, Cleator S, Douek M, Usiskin S, Tobias JS, Vaidya JS, Menopausal hormone therapy for breast cancer patients: what is the current evidence?, Menopause, 2026;33(1):88-117.